Skip to main content

Table 4 Multivariable Generalized Estimating Equation (GEE) models of a gap of 12 months between laboratory measurements

From: Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study

 

Liver (AST/ALT)

Renal (Creatinine)

Metabolic (Lipids)

(N = 3343)

(N = 2955)

(N = 2838)

Odds ratio

95 % CI

p-value

Odds ratio

95 % CI

p-value

Odds ratio

95 % CI

p-value

Province

  British Columbia

Ref

  

Ref

  

Ref

  

  Ontario

1.03

(0.82,1.30)

0.79

0.95

(0.71,1.28)

0.74

2.78

(2.16,3.58)

<0.0001

  Quebec

0.99

(0.74,1.32)

0.94

1.18

(0.86,1.61)

0.31

2.56

(1.96,3.33)

<0.0001

Age at cART initiation (per 10 years)

0.77

(0.70,0.84)

<0.0001

0.73

(0.66,0.81)

<0.0001

0.87

(0.80,0.96)

<0.01

Male

0.92

(0.74,1.15)

0.46

0.97

(0.74,1.28)

0.84

0.77

(0.63,0.94)

0.01

Race

  Caucasian

Ref

  

Ref

  

Ref

  

  Black

1.43

(1.05,1.96)

0.02

1.09

(0.69,1.73)

0.71

1.78

(1.29,2.45)

<0.001

  Aboriginal

1.09

(0.73,1.64)

0.66

0.80

(0.48,1.33)

0.38

1.22

(0.75,1.96)

0.42

  Other

0.52

(0.35,0.75)

<0.001

0.55

(0.35,0.85)

<0.01

0.92

(0.65,1.30)

0.62

  Unknown

1.18

(0.92,1.52)

0.19

0.90

(0.69,1.18)

0.44

1.10

(0.90,1.35)

0.36

HCV and IDU status

  HCV- non-IDU

Ref

  

Ref

  

Ref

  

  HCV+ non-IDU

0.98

(0.67,1.43)

0.92

0.83

(0.52,1.33)

0.44

0.72

(0.50,1.03)

0.07

  HCV- IDU

1.02

(0.65,1.60)

0.92

1.04

(0.59,1.82)

0.89

0.86

(0.51,1.45)

0.58

  HCV+ IDU

2.21

(1.73,2.82)

<0.0001

1.88

(1.40,2.53)

<0.0001

1.70

(1.30,2.23)

<0.001

  Unknown

1.15

(0.88,1.49)

0.30

1.47

(1.12,1.93)

0.01

0.55

(0.44,0.68)

<0.0001

Grade 3 or 4 elevation at previous visit

0.64

(0.44,0.93)

0.02

1.74

(0.51,5.96)

0.38

0.68

(0.54,0.86)

<0.01

VL < 50 copies/mL at gap start

0.67

(0.59,0.77)

<0.0001

0.63

(0.52,0.75)

<0.0001

0.82

(0.72,0.93)

<0.01

CD4 count at gap start

  <200 cells/mm3

Ref

  

Ref

  

Ref

  

  200-350 cells/mm3

0.92

(0.77,1.10)

0.35

1.07

(0.85,1.35)

0.55

1.02

(0.87,1.20)

0.80

  350-500 cells/mm3

0.88

(0.72,1.07)

0.18

1.08

(0.83,1.39)

0.58

1.11

(0.93,1.33)

0.26

  >500 cells/mm3

1.03

(0.84,1.26)

0.76

1.26

(0.97,1.63)

0.09

1.12

(0.93,1.35)

0.23

cART initiation year

  2000

Ref

  

Ref

  

Ref

  

  2001-2005

0.56

(0.45,0.70)

<0.0001

0.58

(0.44,0.77)

0.0001

0.83

(0.64,1.08)

0.16

  >2005

0.37

(0.29,0.48)

<0.0001

0.39

(0.28,0.54)

<0.0001

0.72

(0.55,0.94)

0.02

  1. IDU injection drug use as risk factor for HIV acquisition, HCV+ positive for Hepatitis C, VL viral load
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us